103 results about "Anticarcinogenic Effect" patented technology

The invention discloses a preparation method and application of roasted barley and malt polysaccharide with an anti-cancer effect. The roasted barley malt polysaccharide is a neutral heteropolysaccharide which mainly takes-> 3)-beta-D-Glcp-(1-> and->-beta-D-Glcp-(1->) as main chains, branches exist at O-3 / O-4 positions, and the branch chains are mainly composed of-> 4)-beta-D-Xylp-(1->,-> 3, 4)-beta-D-Xylp-(1-> and alpha-D-Glcp-(1->. The monosaccharide composition comprises arabinose, glucose and xylose in a molar mass ratio of 1.86: 33.43: 1.00, and the molecular weight is 23.81 kDa. In-vitro activity experiments prove that the roasted barley malt polysaccharide disclosed by the invention has a remarkable inhibition effect on proliferation of liver cancer cells, lung cancer cells, breast cancer cells and colorectal cancer cells, particularly on the liver cancer cells, and shows outstanding anti-tumor activity, so that the roasted barley malt polysaccharide is expected to be developed and applied in the fields of foods, health-care products or medicines.

The invention discloses a 5-substituted-3-(arylaminoethyl) benzoxazolone compound and a preparation method and application thereof.The compound takes CO2 as a carbonyl source, the preparation method is simple, raw materials are easy to obtain, and the compound has a good anti-cancer effect on the activity of cancer cells and particularly has a remarkable anti-cancer effect on the cancer cells such as HCCLM3 (human hepatoma carcinoma cells) and MCF-7 (human breast cancer cells).

The invention provides a nano medicinal preparation for tumor treatment as well as a preparation method and application thereof, and relates to the technical field of medicinal preparations. The preparation method of the nano medicinal preparation comprises the following steps: S1, adding metal salt and oxidase into water, uniformly stirring and mixing to form a compound, then adding antibiotics, and continuously stirring and uniformly mixing for reaction to obtain a mixed solution; and S2, centrifuging the mixed solution, collecting the precipitate, washing, and dispersing into water for storage to obtain the nano-drug preparation. The nano medicinal preparation disclosed by the invention can intelligently respond to a tumor microenvironment, efficiently remove fusobacterium nucleatum in tumors and kill tumor cells through synergistic antibacterial and anticancer effects, so that tumor development is inhibited. Moreover, the complex prepared by the invention can enhance the stability of a medicinal preparation, can realize targeted release of the medicine in a tumor microenvironment, and improves the action effect.

The application discloses a combined drug for treating lung cancer. It is found for the first time that lomethixol can be used alone or in combination with other drugs to have a significant anticancer effect on NSCLC patients and NSCLC patients resistant to osimertinib, and in addition, it is found that lomethixol is a potential autophagy inducer and can activate cell autophagy. The application provides a new clinical treatment method for NSCLC patients and NSCLC patients resistant to osimertinib, and has a wide application prospect.

A benzofuran-based N-acylhydrazone derivative according to the present invention has an excellent anticancer effect while having low toxicity and excellent solubility, and thus a pharmaceutical composition comprising the derivative can be usefully used to prevent or treat a cell proliferative disorder including various cancers.

The present invention relates to a peptide binding to OTUB1 and a use thereof. A peptide of a specific sequence having the property of binding to OTUB1 is observed to exhibit an anticancer effect on cancer cells without affecting the cell growth of normal cells, and thus can be usefully used as a composition for preventing, treating, or alleviating cancer diseases.

The invention relates to the technical field of biological medicines, and particularly discloses a compound, a preparation method thereof and application of the compound in preparation of a medicine with an anti-cancer effect. The compound has a structure as shown in a formula I which is described in the specification. Researches show that the compound has a remarkable inhibition effect on the growth of breast cancer and lung cancer cells; further researches show that the compound can also significantly inhibit migration and invasion of breast cancer and lung cancer cells. Therefore, the compound disclosed by the invention is used as an effective component for preparing the medicine with the effects of resisting breast cancer and lung cancer; particularly, the compound has important application value when being used for preparing medicines with effects of resisting metastasis and invasion of breast cancer and lung cancer cells.

The invention provides an application of ginkgetin in enhancing VS4718 or ponatinib in resisting the progress of esophageal squamous cell carcinoma. It is found that ginkgo biflavone can enhance the growth and invasion inhibition effect of VS4718 or ponatinib on esophageal squamous carcinoma cells; ginkgo biflavone is used for enhancing the inhibition effect of VS4718 or ponatinib on glycolipid metabolism of tumor cells, and the ginkgo biflavone is respectively combined with VS4718 or ponatinib to generate a synergistic anti-cancer effect.

The invention relates to a composition containing selenium gluconate and application of the composition in preparation of anti-cancer drugs. The composition comprises a shiitake mushroom extract, a chicory extract and selenium gluconate. Wherein the selenium gluconate is selenium salt of gluconic acid, has an anti-cancer effect, but is easy to generate side effects when being independently used; according to the invention, the mushroom extract, the chicory extract and the selenium gluconate are combined for use, so that the killing power of the composition on cancer cells can be synergistically improved, the immunity can be remarkably improved, the related side effects can be effectively reduced, and the damage to normal cells can be reduced.

The invention relates to the technical field of biological medicines, and particularly discloses a compound or a composition and application of the compound or the composition in preparation of a medicine with an anti-cancer effect. The compound has a structure as shown in a formula I, a formula II or a formula III. Researches show that the compound provided by the invention has an anti-pancreatic cancer effect; further research shows that the composition composed of the compounds with the structures as shown in the formula I and the formula III has a more excellent pancreatic cancer resisting effect, and the pancreatic cancer resisting effect of the composition is greatly higher than that of the single compound with the structure as shown in the formula I or the single compound with the structure as shown in the formula III.

The present invention relates to a methionine sulfoxide reductase B1 inhibitor and an anticancer composition comprising same. More specifically, the present invention relates to 4-[3-(4-ethylphenyl)-5-(4-hydroxyphenyl) -4,5-dihydro -1 H-pyrazol-1-yl]benzene-1-sulfonamide or 6-chloro-10-(4-ethylphenyl)-4-hydroxypyrimido[4,5-b]quinolin-2(10H)-one, which is a MsrB1 inhibitor, and an anticancer composition comprising same. The MsrB1 inhibitor of the present invention has been confirmed to inhibit differentiation into tumor-friendly M2 macrophages and to suppress tumor growth. In addition, the MsrB1 inhibitor of the present invention was found to exhibit anticancer effects through immune regulation within the tumor microenvironment, and thus can be usefully applied as a composition for cancer treatment.

Provided are compositions and methods that include use of micro-RNAs and mimics of the micro-RNAs for treating cancer. Specific ratios of micro-RNAs that have enhanced anti-cancer properties for treating prostate, bladder, and head and neck cancer are provided. The micro-RNAs are conjugated to nanoparticles configured so that exposure to light releases the micro-RNAs from the nanoparticles, thereby allowing the microRNAs to elicit anti-cancer effects.

The present invention pertains to a composition, containing aripiprazole as an active ingredient, for enhancing the anticancer effect of a RAF inhibitor. More specifically, the present invention pertains to a composition for enhancing the anticancer effect of the RAF inhibitor, wherein the composition can treat cancer by acting as an agent for enhancing the anticancer effect of the RAF inhibitor when used in combination therapy with aripiprazole. Administering an effective amount of aripiprazole according to the present invention in combination with the RAF inhibitor is highly effective in enhancing the anticancer effect of the RAF inhibitor, such as by inducing cancer cell death, and thus the composition can be advantageously used as an agent for enhancing the anticancer effect of the RAF inhibitor.

The present invention relates to: an antibody targeting a mutation of KRAS as an intracellular oncoprotein; or a fusion protein in which a cancer cell-penetrating peptide is linked to a single-chain variable fragment of the antibody by a genetic expression method or a chemical bonding method; and a tumor therapeutic use thereof. The fusion protein thus produced has the benefit of maximizing an anti-tumor or anticancer effect of the antibody or the single-chain variable fragment of the antibody targeting an intracellular oncoprotein or an oncomutant protein by effectively invading tumor cells.

The invention relates to the field of biological science and drug carriers, in particular to tumor microenvironment enzyme response type nano-particles, a preparation method and application thereof, and the tumor microenvironment enzyme response type nano-particles comprise at least two structural domains a which are sequences of matrix metalloproteinase substrate peptides; at least one structural domain b which is a sequence of melittin; the structural domain a is connected to the C tail end and the N tail end of the structural domain b; the tumor microenvironment enzyme response type melittin can slowly release melittin in a tumor microenvironment under enzyme response to achieve an anti-cancer effect, can also be used for preparing a nano-drug, and can deliver a ferroptosis small-molecule accelerant RSL3 to the tumor microenvironment in a targeted manner, so that the drug can infiltrate into tumor cells and induce tumor cell death, and the tumor microenvironment enzyme response type melittin has a good anti-cancer effect. The antigens in tumor cells are released, so that tumor immunotherapy and tumor metastasis treatment are realized, and the drug resistance of liver metastatic tumors is eliminated.

The present invention addresses the problem of developing a drug for inhibiting the DNA damage restoration mechanism in a cancer which does not have a mutation in BRCA 1 / 2 and in which homologous recombination repair functions normally.　The inventors of the present invention have clarified that cell death can be induced by inhibiting PARP functions and mitochondrial respiration functions in cells, and indicated that the problem can be solved. In other words, the present invention provides: a method for inducing cell death by inhibiting PARP functions and mitochondrial respiration functions in cells; and a pharmaceutical composition for treating cancer, the pharmaceutical composition containing a PARP inhibitor and a mitochondrial respiration inhibitor.

The present application relates to the field of immunology, in particular to anti-LILRB1 antibodies or antigen-binding fragments thereof, preparation methods and uses, especially anti-LILRB1 nanobodies or antigen-binding fragments thereof, preparation methods and uses. The anti-LILRB1 antibodies or antigen-binding fragments thereof can inhibit the immune escape mechanism of tumor cells, so that immune cells can exhibit their anti-cancer effects.

The present invention relates to the use of sodium pentaborate pentahydrate enriched with boron isotope (10B, 11B) as a chemotherapeutic agent thanks to its anticarcinogenic effect on renal cancer. As a result of the experimental studies performed within the scope of the invention, it has been shown that while the number of renal cancer cells decreased by 50%, this effect occurs by arresting the cell cycle and slowing down cell proliferation, therefore sodium pentaborate pentahydrate enriched with boron isotope can be used as a chemotherapeutic agent in cancer treatment.

The present invention relates to the field of biomedicine technology, and specifically discloses a thiophene-containing pyrimidine compound, a preparation method thereof, and its use in the preparation of drugs with anti-cancer effects. The thiophene-containing pyrimidine compound has a chemical structure represented by formula (I). Studies have shown that the thiophene-containing pyrimidine compound has an inhibitory effect on PLK1 protein kinase; therefore, using it as an active ingredient in the preparation of drugs with anti-cancer effects has important application value. In particular, in existing anti-cancer experiments, the thiophene-containing pyrimidine compound has a better effect on non-small cell lung cancer than the known compound BI2536, showing a more significant anti-non-small cell lung cancer effect.

The present invention relates to a cancer-targeting drug delivery system comprising: a protamine-based self-assembling first nanoparticle including a negatively charged substance; and a heparin-based self-assembling second nanoparticle including a positively charged anticancer agent and Fe3+. Specifically, the present invention provides a drug delivery system that forms aggregates at a tumor site by a guidance effect upon administration of the second nanoparticle after administration of the first nanoparticle, and has an anticancer effect through induction of ferroptosis and immunogenic cell death without exhibiting the anticoagulant effect of heparin.

The invention relates to a composition used as an anti-carcinogenic agent having low cardiotoxicity and high antimicrobial stability. The composition comprises at least one fraction of Heteroctenus junceus scorpion venom, wherein said fraction can be selected from the list comprising: F4, F5.3 and any recognisable and identifiable combination of the two, wherein both fractions have an anti-carcinogenic effect, which is mainly associated with the total or partial inhibition of tumour progression.

The invention relates to preparation of an anti-cancer peptide inhibitor GLP2 with good biocompatibility, stability and excellent anti-cancer activity and application of the anti-cancer peptide inhibitor GLP2 in tumor treatment, and belongs to the field of medicine. The amino acid sequence of the anticancer peptide inhibitor GLP2 is C12H23O-Tyr-Cys-Pro-Tyr-Lys-Ser-Arg-Tyr-Lys-Lys-Pro-Arg-Arg-Pro-Val-Arg-Asn-Tyr-C6H12NO5, the anticancer peptide inhibitor GLP2 is designed on the basis of several important biological characteristics (net positive charge, amphipathy and a PPII spiral structure) of an anticancer peptide, and fatty acid C12H24O2 and monosaccharide C6H13NO5 are coupled to the N end and the C end of the anticancer peptide inhibitor GLP2 respectively. The invention provides a technical scheme for solid-phase synthesis of an anticancer peptide inhibitor skeleton. The GLP2 has excellent in-vitro anticancer activity, good pancreatin stability and biocompatibility. In-vivo anti-cancer experiments show that the designed anti-cancer peptide inhibitor can play an excellent anti-cancer role in a mouse tumor model and is a potential anti-cancer inhibitor with a good application prospect.

The present invention relates to a composition for enhancing the anticancer effect of a MEK inhibitor, the composition comprising aripiprazole as an active ingredient, and more specifically, to a composition for enhancing the anticancer effect of a MEK inhibitor, the composition being capable of treating cancer by acting as an anticancer effect enhancer of the MEK inhibitor when used in combination therapy with aripiprazole, wherein an effective amount of aripiprazole according to the present invention is highly effective in improving the anticancer effect of the MEK inhibitor, such as by inducing cancer cell death, when administered in combination with the MEK inhibitor, and thus the present invention can be effectively used as an agent for improving the anticancer effect of the MEK inhibitor.

The invention discloses a benzimidazole derivative containing an aryl urea structure, a preparation method of the benzimidazole derivative and an anti-cancer effect of the benzimidazole derivative. An indazole ring of an HIF-1alpha classical inhibitor YC-1 is modified into a benzimidazole ring, then an aryl urea structure is introduced into a benzimidazole structure according to a pharmacophore splicing principle to obtain the novel benzimidazole derivative containing the aryl urea structure and having high biological activity, the range of existing anti-cancer compounds is widened, and the novel benzimidazole derivative containing the aryl urea structure is suitable for industrial production. The compound can be continuously optimized as a lead compound. The anti-cancer capsule has a good anti-cancer effect and meets the requirements of the field of medicines.

The invention discloses a thymol-platinum (IV) complex as well as a preparation method and application thereof. Thymol is connected to at least one axial side of the tetravalent platinum coordination center; specifically, one axial side of a platinum (IV) coordination center is connected with one molecule thymol to form a monosubstituted tetravalent platinum complex; or the two axial sides of the platinum (IV) coordination center are respectively connected with one molecule thymol; or the axial side of the platinum (IV) coordination center is connected with a molecule thymol, and the other side of the platinum (IV) coordination center is connected with a carbon (nitrogen) long-chain group to form a disubstituted tetravalent platinum complex; compared with a traditional platinum drug, the thymol-platinum (IV) complex has better tumor killing ability, the cytotoxicity is improved by 147 times to the maximum compared with cis-platinum, and the thymol-platinum (IV) complex especially has a better anti-cancer effect on pancreatic cancer. The novel medicine is simple in synthesis process and low in cost, the curative effect of drug combination is greatly improved, compared with traditional bivalent platinum and similar tetravalent platinum drugs, the novel medicine has the advantages of being good in curative effect, small in side effect and the like, and a new thought is provided for modification of tetravalent platinum.

The effects of compositions 2-bromo-2-nitro-1,3-propanediol are discussed herein, including an anticancer effect of the compositions. Methods related to treating cancer in a subject comprising administering compositions comprising 2-bromo-2-nitro-1,3-propanediol and methods related to inhibiting the activity of thioredoxin reductase are also provided. Dosage ranges are disclosed along with compatible treatment regimens.

This invention discloses an epigenetic drug targeting lncRNA-PSF interaction, its composition, and its application. First, this invention synthesizes an epigenetic drug targeting lncRNA-PSF interaction as shown in formula (I) or formula (II). Compared with existing technologies, the epigenetic drugs shown in formulas (I) and (II) can inhibit lncRNA-PSF interaction, alter the cell cycle by increasing the expression of p27 and p53 proteins, arrest cancer cells in the G2 / M phase, and thus exert an anti-cancer effect. When the epigenetic drugs shown in formulas (I) and (II) are used in combination with immunosuppressants, they can enhance the effect of immunosuppressants, increase antigen presentation by cancer cells, and reduce their immune escape, thus becoming a novel anti-cancer sensitization strategy.

The invention relates to the field of traditional Chinese medicine formulas, and particularly discloses a traditional Chinese medicine formula with an anticancer effect and a preparation method thereof, and the traditional Chinese medicine formula is prepared from the following raw materials in parts by weight: 10-30 parts of radix aconiti agrestis, 15-40 parts of antler cap, 20-50 parts of selfheal, 10-35 parts of radix clematidis, 15-45 parts of radix rubiae and 20-60 parts of dandelion. Through precise compatibility of six medicinal materials including radix aconiti agrestis, antler cap, selfheal, radix clematidis, radix rubiae and dandelion, a core mechanism breakthrough of multi-target synergistic inhibition of tumor growth and metastasis is realized. Compared with a traditional anti-cancer traditional Chinese medicine formula which is numerous and jumbled and single in effect, the formula takes the antler cap as a monarch drug to lead the whole formula, so that the anti-cancer activity of the radix aconiti agrestis is enhanced, toxicity is neutralized by virtue of the heat clearing and stagnation eliminating characteristics of selfheal and dandelion, and the unique treatment advantage of counteracting toxic substances without hurting the body resistance is formed.